Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13

Benzinga · 3d ago
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.